electroCore Announces Publication in Nature Reviews Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled,
“Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs. Diana Wei and Peter Goadsby in Nature Reviews: Neurology.1
The paper reviews data on existing and emerging treatments for the acute and preventive treatment of cluster headache, as well as insights into the pathophysiology of cluster headache. Cluster headache is a debilitating primary headache disorder that affects approximately 0.1% of populations studied, a prevalence similar to that of multiple sclerosis.
Among the emerging treatments, electrocore’s gammaCore is identified as the only therapy that has been shown to be effective in clinical trials for both the acute treatment of episodic cluster headache as well as the preventive treatment of cluster headache. This dual ability offers a unique, nonpharmaceutical advantage to patients suffering from cluster headache who are looking for a treatment that can both acutely decrease or eliminate the pain from an acute cluster headache in as soon as 15 minutes, as well as decrease the number of weekly attacks they experience.
“Great strides have been made in the treatment of cluster headache in the past decade,” commented Dr. Peter Goadsby, Professor of Neurology at UCLA, and co-author of the study. “Treatment options such as nVNS may benefit individuals with cluster headache and have a substantial economic impact both directly by decreasing the overall cost of healthcare and indirectly by reducing absence from work and reduced work efficiency due to cluster headaches.”
“We compliment the authors on their rigorous review of current and emerging treatment options and on the publication, which highlights progress in the study of cluster headache and the evolution of its treatment. nVNS, which is unique in its ability to be used acutely or preventively by patients suffering from cluster headache, is ideally suited to help these patients manage their devastating attacks while decreasing the overall costs to healthcare systems,” said Eric Liebler, Senior Vice President of Neurology of electroCore.